Survey-weighted analyses across 11 NHANES cycles (1999-2000 through 2021-2023) revealed no statistically significant linear trends in the prevalence of chronic kidney disease or prior cardiovascular disease. The authors reported stable population-level prevalence for hypertension and dyslipidemia when evaluated as categorical outcomes. Yet mean physiologic values changed: average systolic blood pressure fell from 124.2 to 120.2 mm Hg, and mean total cholesterol declined from 203.6 to 188.1 mg/dL. Those parallel findings—stable disease prevalence but lower mean values—reflect shifts in measurement and management rather than simple absence of change.
Obesity increased sharply. The prevalence rose from 47.4% to 57.2% over the observation window. Class III obesity more than doubled, moving from 4.7% to 9.7%. Diabetes prevalence also increased, from 8.2% to 12.7%. The study team observed rising awareness of diabetes, but they noted that trends in diabetes treatment were nonsignificant. Glycemic control did not keep pace with rising prevalence: the proportion meeting glycemic-control targets peaked at 51.2% in 2003-2004 and declined to 41.9% by 2021-2023 (P for nonlinearity <0.001). These data indicate widening metabolic risk despite some improvements in screening or diagnosis.
Awareness and treatment for hypertension increased over time, the authors reported. Control, however, showed a nonlinear trajectory. Blood pressure control across the US adult population reached a high of 32.5% in the 2013-2014 NHANES cycle, then declined to 21.5% in 2021-2023. Meanwhile mean systolic blood pressure values continued a modest downward trend. The apparent paradox—declining mean systolic values with falling categorical control—may reflect changing thresholds, measurement protocols, or uneven treatment effectiveness across subgroups; the source did not report detailed subgroup-level mechanisms beyond noting subgroup analyses were performed.
The study team found broad improvements in lipid profiles. Total cholesterol and other lipid measures decreased over the study period. Awareness and treatment rates for dyslipidemia rose. LDL cholesterol control improved substantially, increasing from 17.0% to 34.2% between the earliest and latest cycles. Those shifts occurred alongside falling population mean cholesterol values and higher rates of lipid therapy, although the preprint did not provide granular medication-class breakdowns in the abstract.
The investigators used PREVENT equations to estimate multidecade risk among adults without self-reported cardiovascular disease. Predicted 10-year total CVD risk declined modestly from 5.66% to 5.28% over the study interval. Predicted 10-year atherosclerotic CVD (ASCVD) risk declined by 0.16 percentage points per decade (95% CI, 0.22 to 0.09). By contrast, predicted 10-year heart failure risk increased by 0.10 per decade (95% CI, 0.03-0.17). The 2021-2023 point estimates for the ASCVD and HF risk components were reported as nearly identical in absolute terms (3.20% and 3.19%). Thirty-year risk estimates showed a similar divergence between ASCVD and HF trajectories. These modeled predictions reflect population shifts in risk factor composition—improving smoking and lipids versus rising obesity and diabetes.
The analysis included 60,199 nonpregnant adults aged 20 years or older pooled across NHANES surveys. The authors applied age-standardized, survey-weighted regression to assess linear trends, subgroup differences, and sensitivity to measurement changes. They evaluated awareness, treatment, and control for hypertension, dyslipidemia, and diabetes. PREVENT risk equations were used to derive predicted 10- and 30-year risks among participants without self-reported CVD. All data were publicly available from NHANES; the preprint notes NHANES protocols were approved by the National Center for Health Statistics Research Ethics Review Board and participants provided informed consent. The source explicitly states this manuscript is a preprint and has not been peer reviewed.
This report is a secondary analysis of NHANES data; the authors relied on the public dataset and on self-reported history to exclude participants with prior cardiovascular disease. The preprint status means the findings have not undergone peer review. The abstract did not provide detailed subgroup or medication-class breakdowns, nor did it report sample-size strata for every subgroup in the text summarized here. The source did not specify certain analytic choices in the abstract—such as full covariate lists used in adjusted models or the handling of missing data—so readers should consult the full preprint PDF for those details. Key unanswered questions remain: what drove the post-2014 decline in blood pressure control at the population level, which subgroups bore the greatest increases in class III obesity and diabetes, and how changes in treatment patterns by drug class affected lipid and glycemic control. These items require the full manuscript review and independent peer evaluation before clinical or policy translation.